Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Labor, Induced | 13 | 2025 | 26 | 5.040 |
Why?
|
| Oxytocics | 7 | 2022 | 13 | 3.390 |
Why?
|
| Cervical Ripening | 7 | 2021 | 11 | 2.380 |
Why?
|
| Pre-Eclampsia | 4 | 2023 | 70 | 2.050 |
Why?
|
| Chorioamnionitis | 4 | 2025 | 15 | 1.950 |
Why?
|
| Oxytocin | 4 | 2021 | 44 | 1.930 |
Why?
|
| Misoprostol | 4 | 2020 | 9 | 1.860 |
Why?
|
| Pregnancy | 30 | 2025 | 2366 | 1.840 |
Why?
|
| Postpartum Hemorrhage | 3 | 2023 | 6 | 1.690 |
Why?
|
| Cesarean Section | 6 | 2025 | 100 | 1.390 |
Why?
|
| Delivery, Obstetric | 2 | 2020 | 55 | 1.150 |
Why?
|
| Cervix Uteri | 2 | 2020 | 58 | 1.070 |
Why?
|
| Premature Birth | 5 | 2022 | 114 | 1.000 |
Why?
|
| Endometritis | 2 | 2023 | 4 | 0.990 |
Why?
|
| Hypertension, Pregnancy-Induced | 3 | 2023 | 50 | 0.970 |
Why?
|
| Catheters | 3 | 2022 | 76 | 0.960 |
Why?
|
| Amniotomy | 1 | 2025 | 2 | 0.950 |
Why?
|
| Neonatal Sepsis | 1 | 2025 | 4 | 0.950 |
Why?
|
| Urinary Catheterization | 3 | 2021 | 20 | 0.870 |
Why?
|
| Infant, Newborn | 13 | 2025 | 1416 | 0.830 |
Why?
|
| Polyhydramnios | 1 | 2023 | 2 | 0.830 |
Why?
|
| Eclampsia | 1 | 2021 | 3 | 0.710 |
Why?
|
| Prenatal Care | 3 | 2020 | 169 | 0.680 |
Why?
|
| Female | 31 | 2025 | 33857 | 0.670 |
Why?
|
| Dinoprostone | 1 | 2020 | 41 | 0.640 |
Why?
|
| Cerclage, Cervical | 2 | 2020 | 4 | 0.610 |
Why?
|
| Private Practice | 1 | 2015 | 8 | 0.470 |
Why?
|
| Humans | 31 | 2025 | 64913 | 0.470 |
Why?
|
| Pregnancy, Multiple | 1 | 2014 | 10 | 0.440 |
Why?
|
| Smoke-Free Policy | 1 | 2014 | 9 | 0.440 |
Why?
|
| Pregnancy in Adolescence | 1 | 2014 | 21 | 0.440 |
Why?
|
| Ambulatory Care | 1 | 2017 | 316 | 0.430 |
Why?
|
| Genetic Testing | 1 | 2015 | 141 | 0.430 |
Why?
|
| Anaphylaxis | 1 | 2014 | 41 | 0.420 |
Why?
|
| Retrospective Studies | 8 | 2025 | 6831 | 0.410 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 304 | 0.410 |
Why?
|
| Guideline Adherence | 1 | 2015 | 302 | 0.390 |
Why?
|
| Adult | 15 | 2025 | 17284 | 0.390 |
Why?
|
| Time Factors | 5 | 2025 | 3757 | 0.360 |
Why?
|
| Gestational Age | 4 | 2025 | 195 | 0.330 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2015 | 705 | 0.320 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2022 | 799 | 0.320 |
Why?
|
| Maternal Age | 1 | 2009 | 33 | 0.310 |
Why?
|
| Maternal Mortality | 1 | 2009 | 16 | 0.310 |
Why?
|
| Administration, Intravaginal | 3 | 2019 | 12 | 0.280 |
Why?
|
| Progestins | 3 | 2022 | 29 | 0.280 |
Why?
|
| Progesterone | 2 | 2022 | 165 | 0.270 |
Why?
|
| Catheterization | 2 | 2018 | 111 | 0.260 |
Why?
|
| Young Adult | 6 | 2020 | 4784 | 0.260 |
Why?
|
| Pregnancy Complications | 1 | 2009 | 384 | 0.220 |
Why?
|
| Watchful Waiting | 1 | 2023 | 32 | 0.200 |
Why?
|
| Anti-Bacterial Agents | 2 | 2020 | 803 | 0.200 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 726 | 0.200 |
Why?
|
| Life Style | 1 | 2025 | 320 | 0.190 |
Why?
|
| Traction | 1 | 2022 | 5 | 0.180 |
Why?
|
| Pregnancy Outcome | 3 | 2025 | 197 | 0.180 |
Why?
|
| Masks | 1 | 2022 | 20 | 0.180 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2020 | 93 | 0.180 |
Why?
|
| Magnesium Sulfate | 1 | 2021 | 9 | 0.180 |
Why?
|
| Family | 1 | 2023 | 245 | 0.170 |
Why?
|
| Philadelphia | 2 | 2020 | 24 | 0.170 |
Why?
|
| Pregnancy Trimester, First | 2 | 2020 | 24 | 0.170 |
Why?
|
| RNA, Viral | 1 | 2022 | 266 | 0.170 |
Why?
|
| Perinatal Mortality | 1 | 2020 | 2 | 0.160 |
Why?
|
| Tocolytic Agents | 1 | 2020 | 3 | 0.160 |
Why?
|
| Labor Stage, First | 1 | 2020 | 6 | 0.160 |
Why?
|
| Pregnancy, Twin | 1 | 2020 | 7 | 0.160 |
Why?
|
| Apgar Score | 1 | 2020 | 10 | 0.160 |
Why?
|
| Health Promotion | 1 | 2025 | 513 | 0.160 |
Why?
|
| Milk, Human | 1 | 2022 | 99 | 0.160 |
Why?
|
| Anesthesia, Epidural | 1 | 2020 | 20 | 0.160 |
Why?
|
| Asymptomatic Diseases | 1 | 2020 | 52 | 0.160 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 218 | 0.160 |
Why?
|
| Hydroxyprogesterones | 2 | 2022 | 5 | 0.160 |
Why?
|
| Cervical Length Measurement | 2 | 2020 | 6 | 0.150 |
Why?
|
| Breast Feeding | 1 | 2022 | 164 | 0.150 |
Why?
|
| Erythromycin | 1 | 2019 | 4 | 0.150 |
Why?
|
| Uterine Hemorrhage | 1 | 2019 | 20 | 0.150 |
Why?
|
| Parity | 2 | 2018 | 71 | 0.150 |
Why?
|
| Azithromycin | 1 | 2019 | 34 | 0.150 |
Why?
|
| Aspirin | 1 | 2020 | 171 | 0.140 |
Why?
|
| Mothers | 1 | 2022 | 279 | 0.140 |
Why?
|
| Arterial Pressure | 1 | 2018 | 27 | 0.140 |
Why?
|
| Depression, Postpartum | 1 | 2020 | 120 | 0.140 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2020 | 233 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2020 | 3303 | 0.140 |
Why?
|
| Cytokines | 1 | 2022 | 953 | 0.130 |
Why?
|
| Delaware | 1 | 2017 | 8 | 0.130 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2018 | 202 | 0.130 |
Why?
|
| Abortion, Habitual | 1 | 2016 | 8 | 0.130 |
Why?
|
| Pain | 1 | 2018 | 398 | 0.120 |
Why?
|
| New Jersey | 1 | 2015 | 24 | 0.120 |
Why?
|
| Observational Studies as Topic | 1 | 2015 | 66 | 0.110 |
Why?
|
| Treatment Failure | 1 | 2015 | 206 | 0.110 |
Why?
|
| Administration, Buccal | 1 | 2014 | 2 | 0.110 |
Why?
|
| Risk Factors | 3 | 2016 | 5407 | 0.110 |
Why?
|
| Hypertension | 1 | 2020 | 610 | 0.110 |
Why?
|
| Adolescent | 2 | 2015 | 6305 | 0.110 |
Why?
|
| Cohort Studies | 4 | 2022 | 2609 | 0.100 |
Why?
|
| Analgesics, Opioid | 1 | 2018 | 525 | 0.100 |
Why?
|
| Depression | 1 | 2020 | 892 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 655 | 0.100 |
Why?
|
| Evidence-Based Medicine | 1 | 2014 | 456 | 0.090 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2009 | 34 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2017 | 5774 | 0.070 |
Why?
|
| United States | 3 | 2020 | 8067 | 0.070 |
Why?
|
| Proteomics | 2 | 2022 | 291 | 0.070 |
Why?
|
| Middle Aged | 3 | 2022 | 18169 | 0.070 |
Why?
|
| Diabetes, Gestational | 1 | 2009 | 142 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 295 | 0.070 |
Why?
|
| Massachusetts | 2 | 2023 | 2143 | 0.060 |
Why?
|
| Anthropometry | 1 | 2025 | 86 | 0.060 |
Why?
|
| Birth Weight | 1 | 2025 | 83 | 0.050 |
Why?
|
| Consensus | 1 | 2023 | 181 | 0.050 |
Why?
|
| 17-alpha-Hydroxyprogesterone | 1 | 2022 | 3 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2025 | 888 | 0.040 |
Why?
|
| Immunoglobulin A | 1 | 2022 | 102 | 0.040 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2020 | 6 | 0.040 |
Why?
|
| Birth Intervals | 1 | 2020 | 2 | 0.040 |
Why?
|
| Gynecological Examination | 1 | 2020 | 6 | 0.040 |
Why?
|
| Indomethacin | 1 | 2020 | 23 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 315 | 0.040 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 36 | 0.040 |
Why?
|
| Puerto Rico | 1 | 2020 | 137 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 465 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2022 | 326 | 0.040 |
Why?
|
| Amoxicillin | 1 | 2019 | 8 | 0.040 |
Why?
|
| Ampicillin | 1 | 2019 | 12 | 0.040 |
Why?
|
| Dilatation | 1 | 2019 | 34 | 0.040 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2019 | 12 | 0.040 |
Why?
|
| Vaccination | 1 | 2022 | 374 | 0.040 |
Why?
|
| Hematocrit | 1 | 2018 | 33 | 0.040 |
Why?
|
| Exercise | 1 | 2025 | 960 | 0.030 |
Why?
|
| Societies, Medical | 1 | 2020 | 400 | 0.030 |
Why?
|
| Pain Measurement | 1 | 2018 | 340 | 0.030 |
Why?
|
| Antihypertensive Agents | 1 | 2018 | 178 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2019 | 852 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 1688 | 0.030 |
Why?
|
| Obesity | 1 | 2025 | 1263 | 0.030 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 142 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2018 | 189 | 0.030 |
Why?
|
| Biomarkers | 1 | 2022 | 1472 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1413 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2016 | 414 | 0.030 |
Why?
|
| Length of Stay | 1 | 2019 | 826 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2016 | 755 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2018 | 445 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2016 | 2092 | 0.020 |
Why?
|